Table 2 Solubility assessment for representative MK2 constructs.
From: Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
MK2 Construct | Solubility | |||
|---|---|---|---|---|
Backbone | Mutation(s) | 18°C | 27°C | 37°C |
41–364 | -- | Low | Low | Low |
41–364 | K64A | Low | Low | Low |
41–364 | Δ(L220-G236) | High | High | High |
41–364 | T222E | Low | Low | Low |
41–364 | K330A | Low | Low | Low |
41–364 | T334E | Low | Low | Low |
41–364 | K343A, K344A, K364A | Low | Low | Low |
47–366 | -- | High | High | Medium |
47–366 | K64A | High | High | Medium |
47–366 | K84A | High | Med | Low |
47–366 | Δ(L220-G236) | High | High | High |
47–366 | T222E | High | High | Low |
47–366 | T222E, T334E | Low | Low | Low |
47–366 | T334E | Low | Low | Low |